One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
1807 articles with Amgen
Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen's Oncology Assets, Including BiTE® Molecules
Amgen Golden Tickets Provide Startup Companies With Free Lab Space to Further Advance Innovative Science and Technology
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab).
Approval Based on Results That Demonstrated Nplate Successfully Increased and Sustained Platelet Counts in Children Affected by Rare Blood Disorder
Shares of New Jersey-based Advaxis have plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated its collaboration on an immuno-oncology program. The deal between the two companies was first inked in 2016 and had a value of up to $540 million.
deCODE Genetics, An Amgen Subsidiary, And SomaLogic Announce Collaboration To Perform Large-Scale Protein Analysis Of Up To 40,000 Human Samples
Largest-ever Protein Measurement Study Enhances deCODE's Efforts in Basic Research, Drug Discovery and Novel Protein-based Diagnostics
Amgen Donates $93 Million Worth of Cancer Medicines
White Americans make up the vast majority of clinical trial participants, despite evidence that some cancers affect minority populations in greater numbers.
Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions
Amgen (NASDAQ:AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company's capabilities and resources to identify clinical gaps for some of the healthcare system's most difficult-to-treat diseases
Amgen (NASDAQ:AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have teamed up to support more equitable access to clinical trials for cancer patients in the U.S.
Amgen today announced that its Board of Directors declared a $1.45 per share dividend for the first quarter of 2019.
Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018
Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia
At the 60th American Society of Hematology (ASH) Annual Meeting & Exposition, Amgen released the first clinical data from two separate Phase I clinical trials of novel BiTE immunotherapies.
Amgen will present at the Citi Global Healthcare Conference at 12:35 p.m. ET on Thursday, Dec. 6, 2018, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at the conference.
Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the repo...
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Amgen and UCB today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVENITYTM (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on Jan. 16, 2019.
Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition on Monday, Dec. 3, 2018, at 8 p.m. PT. David M. Reese, M.D.,
University of Toronto Mississauga and Local Teachers Bring Transformative Biotechnology Education to Local Classrooms
The University of Toronto Mississauga (UTM), in collaboration with the Amgen Foundation and Amgen Canada, is helping transform local science education and ignite a life-long love of science in students in schools across Mississauga and the Greater Toronto Area (GTA).
Amgen (NASDAQ:AMGN) will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday, Nov. 27, 2018, in New York City and at the Evercore ISI Healthcare Conference at 11 a.m. ET on Wednesday, Nov. 28, 2018, in Boston. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at the conferences.